Anna Mandinova

SeylanMED, Inc. engages in the development of topical akt inhibitor as a treatment for seborrheic keratosis. The company was founded by Victor Neel and Anna Mandinova and is headquartered in Berkeley, CA.

NFlection Therapeutics, Inc. operates as a biotechnology company. It focuses on the development of therapies for Neurofibromatosis. The company was founded by Mark de Souza and Michael Wootton in 2014 and is headquartered in Wayne, PA.

FIBRX Derm, Inc. develops anti-scarring therapeutic for patients with Dystrophic Epidermolysis Bullosa. The company was founded by Mark de Souza, James W. Fordyce and Erkki Ruoslahti and is headquartered in Berkeley, CA.

Chromaderm, Inc. operates as a clinical stage biotech company. It develops topical PKC-beta inhibitor. The company was founded by Barbara A. Gilchrest, Mark de Souza and James W. Fordyce and is headquartered in Cambridge, MA.

SonALAsense, Inc. provides ALA Sonodynamic Therapy for the treatment of Glioblastoma Multiforme. The company was founded by Stuart Marcus and is headquartered in Berkeley, CA.

Phoenicis Therapeutics, Inc. is a private company that is focused on developing therapies for rare dermatological disorders. The company is based in Hingham, MA. The company's goal is to improve the lives of those who suffer from these conditions. The CEO of the company is Deborah Ramsdell.

NF2 Therapeutics, Inc. develops therapies. The American company was founded by Michael Wootton, Mark P de Souza, Scott Plotkin. Michael Wootton has been the CEO since incorporation.